Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
INVA | US
0.11
0.56%
Healthcare
Biotechnology
30/06/2024
04/10/2024
19.67
19.57
19.83
19.54
Innoviva Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA a once-daily combination medicine consisting of a LABA vilanterol (VI) an inhaled corticosteroid (ICS) and fluticasone furoate; ANORO ELLIPTA a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA VI; and TRELEGY ELLIPTA a once-daily combination medicine consisting of an ICS LAMA and LABA. Innoviva Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance Inc. and changed its name to Innoviva Inc. in January 2016. Innoviva Inc. was incorporated in 1996 and is headquartered in Burlingame California.
View LessLow 6-Month Volatility (<30%)
Low Market Beta (-0.4 to 0.8)
Value Stock (Price to Book < 3)
Strong Operating Margin (> 25%)
Strong Revenue Growth (> 10%)
Strong Sharpe Ratio (> 1.2)
Smallcap (300M - 2B USD)
High Short percentage (> 15%)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
19.5%1 month
18.7%3 months
19.7%6 months
19.6%10.92
-
1.82
0.68
0.37
7.18
4.36
0.24
199.53M
1.23B
1.23B
-
54.74
10.40
23.30
23.83
27.95
36.92
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
1.10
Range1M
1.46
Range3M
3.98
Rel. volume
0.52
Price X volume
5.57M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Tarsus Pharmaceuticals Inc | TARS | Biotechnology | 33.89 | 1.31B | 3.48% | n/a | 28.62% |
ELVN | ELVN | Biotechnology | 27.53 | 1.30B | 8.81% | n/a | 0.06% |
Avadel Pharmaceuticals plc | AVDL | Biotechnology | 13.09 | 1.26B | 0.23% | n/a | 53.59% |
Mesoblast Limited | MESO | Biotechnology | 10.81 | 1.26B | 23.40% | n/a | 24.76% |
Wave Life Sciences Ltd | WVE | Biotechnology | 8.41 | 1.24B | -4.76% | n/a | 656.70% |
ANI Pharmaceuticals Inc | ANIP | Biotechnology | 57.83 | 1.22B | 0.57% | 49.40 | 68.04% |
Fluent Inc | COGT | Biotechnology | 11.11 | 1.22B | 3.64% | n/a | 4.87% |
PHATHOM PHARMACEUTICALS INC. | PHAT | Biotechnology | 17.25 | 1.20B | 2.92% | n/a | -216.56% |
ARCUTIS BIOTHERAPEUTICS INC. | ARQT | Biotechnology | 10.02 | 1.17B | -2.05% | n/a | 111.34% |
Travere Therapeutics Inc. | TVTX | Biotechnology | 15.23 | 1.16B | 9.81% | n/a | 2662.08% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Pitney Bowes Inc | PBI | Building Products & Equipment | 6.92 | 1.24B | 1.91% | n/a | -571.93% |
ARLO TECHNOLOGIES INC | ARLO | Building Products & Equipment | 11.47 | 1.15B | 0.09% | n/a | 19.46% |
Camping World Holdings Inc | CWH | Recreational Vehicles | 23.44 | 1.06B | -0.38% | n/a | 3644.76% |
Malibu Boats Inc | MBUU | Recreational Vehicles | 39.7 | 793.63M | -0.68% | n/a | 1.50% |
Latham Group Inc. | SWIM | Building Products & Equipment | 6.64 | 767.43M | 0.00% | 61.27 | 77.00% |
Ennis Inc | EBF | Building Products & Equipment | 24.31 | 631.67M | 2.36% | 15.15 | 2.42% |
ACCO Brands Corporation | ACCO | Building Products & Equipment | 5.25 | 502.94M | -0.19% | n/a | 174.23% |
Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 11.63 | 366.05M | 0.00% | 47.92 | 88.92% |
ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 21.28 | 334.47M | -4.23% | n/a | 286.96% |
Marine Products Corporation | MPX | Recreational Vehicles | 9.47 | 328.78M | 0.21% | 13.24 | 0.00% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | 7.18 | 0.76 | Expensive |
Ent. to Revenue | 4.36 | 3,674.48 | Cheaper |
PE Ratio | 10.92 | 38.01 | Cheaper |
Price to Book | 1.82 | 14.10 | Cheaper |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 19.73 | 74.67 | Lower Risk |
Debt to Equity | 0.68 | -1.82 | Expensive |
Debt to Assets | 0.37 | 0.26 | Expensive |
Market Cap | 1.23B | 3.73B | Emerging |